Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Drugs that inhibit bone resorption ('anti-resorptives') continue to dominate the therapy of bone diseases characterized by enhanced bone destruction, including Paget's disease, osteoporosis and cancers. The historic use of oestrogens for osteoporosis led on to SERMs (Selective Estrogen Receptor Modulators, e.g. raloxifene and bazedoxifene). Currently the mainstay of treatment worldwide is still with bisphosphonates, as used clinically for over 40 years. The more recently introduced anti-RANK-ligand antibody, denosumab, is also very effective in reducing vertebral, non-vertebral and hip fractures. Odanacatib is the only cathepsin K inhibitor likely to be registered for clinical use. The pharmacological basis for the action of each of these drug classes is different, enabling choices to be made to ensure their optimal use in clinical practice.

Original publication

DOI

10.1016/j.coph.2015.05.005

Type

Journal article

Journal

Current opinion in pharmacology

Publication Date

03/06/2015

Volume

22

Pages

115 - 130

Addresses

The Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, United Kingdom; The Mellanby Centre for Bone Research, University of Sheffield Medical School, Sheffield S10 2RX, United Kingdom. Electronic address: graham.russell@ndorms.ox.ac.uk.

Keywords

Animals, Humans, Bone Diseases, Bone Resorption, Biphenyl Compounds, Diphosphonates, Selective Estrogen Receptor Modulators, Bone Density Conservation Agents, Denosumab